Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

神经生长因子 耐受性 医学 不利影响 腺相关病毒 运动障碍 内科学 帕金森病 神经营养因子 临床试验 疾病 肿瘤科 胶质细胞源性神经生长因子 载体(分子生物学) 生物 受体 重组DNA 基因 生物化学
作者
William J. Marks,Jill L. Ostrem,L. Verhagen,Philip A. Starr,Paul Larson,Roy A.E. Bakay,R. L. Taylor,Deborah A. Cahn‐Weiner,A. Jon Stoessl,C. Warren Olanow,Raymond T. Bartus
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:7 (5): 400-408 被引量:584
标识
DOI:10.1016/s1474-4422(08)70065-6
摘要

Summary

Background

There is an urgent need for therapies that slow or reverse the progression of Parkinson's disease (PD). Neurotrophic factors can improve the function of degenerating neurons and protect against further neurodegeneration, and gene transfer might be a means to deliver effectively these factors to the brain. The aim of this study was to assess the safety, tolerability, and potential efficacy of gene delivery of the neurotrophic factor neurturin.

Methods

In this phase I, open-label clinical trial, 12 patients aged 35–75 years with a diagnosis of PD for at least 5 years in accordance with the UK Brain Bank Criteria received bilateral, stereotactic, intraputaminal injections of adeno-associated virus serotype 2–neurturin (CERE-120). The first six patients received doses of 1·3×1011 vector genomes (vg)/patient, and the next six patients received 5·4×1011 vg/patient. This trial is registered with ClinicalTrials.gov, number NCT00252850.

Findings

The procedure was well tolerated. Extensive safety monitoring in all patients revealed no clinically significant adverse events at 1 year. Several secondary measures of motor function showed improvement at 1 year; for example, a mean improvement in the off-medication motor subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) of 14 points (SD 8; p=0.000121 [36% mean increase; p=0.000123]) and a mean increase of 2·3 h (2; 25% group mean increase; p=0·0250) in on time without troublesome dyskinesia were seen. Improvements in several secondary measures were not significant, including the timed walking test in the off condition (p=0·053), the Purdue pegboard test of hand dexterity (p=0·318), the reduction in off time (p=0·105), and the activities of daily living subscore (part II) of the UPDRS (p=0·080). 18F-levodopa-uptake PET did not change after treatment with either dose of CERE-120.

Interpretation

The initial data support the safety, tolerability, and potential efficacy of CERE-120 as a possible treatment for PD; however, these results must be viewed as preliminary until data from blinded, controlled clinical trials are available.

Funding

Ceregene; Michael J Fox Foundation for Parkinson's Research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Akim的应助被翁振生采纳,获得10
刚刚
coolru的应助被闪闪新晴采纳,获得10
1秒前
1秒前
Jam完成签到,获得积分10
1秒前
阮婷发布了新的文献求助10
1秒前
1秒前
要超级无敌开心完成签到 ,获得积分10
2秒前
2秒前
3秒前
阿戈美拉丁完成签到,获得积分10
3秒前
wj发布了新的文献求助10
4秒前
自由的诗霜完成签到,获得积分10
5秒前
LSF发布了新的文献求助10
5秒前
大胆小松鼠完成签到,获得积分10
6秒前
斯文败类的应助被闪闪凝梦采纳,获得10
6秒前
7秒前
可爱的函函的应助被zz采纳,获得10
7秒前
柒玖发布了新的文献求助10
7秒前
7秒前
8秒前
8秒前
谢美阳阳的应助被fcyyc采纳,获得10
8秒前
8秒前
9秒前
嘤嘤嘤发布了新的文献求助30
9秒前
准好好完成签到,获得积分10
11秒前
11秒前
文献下载中完成签到,获得积分10
11秒前
流年发布了新的文献求助10
11秒前
11秒前
Lisss完成签到,获得积分10
12秒前
12秒前
gxgxnn发布了新的文献求助10
12秒前
14秒前
Atopos完成签到,获得积分10
14秒前
14秒前
甜美香之完成签到 ,获得积分10
15秒前
Qin完成签到,获得积分10
15秒前
16秒前
你好发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182147
求助须知:如何正确求助?哪些是违规求助? 9571790
关于积分的说明 21820037
捐赠科研通 7778601
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479652